Economic analysis of recombinant activated factor VII versus
plasma-derived activated prothrombin complex concentrate in
mild to moderate bleeds: Haemophilia registry data from the
Czech Republic

J 2012

Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic

SALAJ, Peter; Miroslav PENKA; Petr SMEJKAL; Vera GEIEROVA; Petra OVESNÁ et al.

Základní údaje

Originální název

Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic

Autoři

SALAJ, Peter; Miroslav PENKA; Petr SMEJKAL; Vera GEIEROVA; Petra OVESNÁ ; Petr BRABEC; Petr CETKOVSKÝ; Radovan KUBES; Johan MESTERTON a Peter LINDGREN

Vydání

Thrombosis Research, 2012, 0049-3848

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.133

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00060984

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.thromres.2012.02.005

UT WoS

000303433500011

Klíčová slova anglicky

Cost-effectiveness; Haemophilia; Plasma-derived activated prothrombin complex concentrate; Recombinant factor VIIa; Registry

Příznaky

Mezinárodní význam

Změněno: 22. 4. 2013 18:57, Soňa Böhmová

Anotace

V originále

Several studies suggest that recombinant activated factor VII (rFVIIa) is more cost-effective than plasma-derived activated prothrombin complex concentrate (pd-aPCC) in haemophilia with inhibitors. However, most do not consider differences between treated patients. This study compared the pharmacoeconomics of rFVIIa versus pd-aPCC treatment of mild to moderate bleeds in inhibitor patients, taking co-variables into account. Methods The HemoRec and HemIS registries capture exhaustive bleeding data in inhibitor patients in the Czech Republic. For each bleed, patient and bleed characteristics, treatment outcomes and bypassing agent use were retrospectively analysed, and direct costs of care per bleed calculated. Generalised Linear Model regression methods with cluster effect were employed to account for the possibility of several bleedings from the same patient. Results There were 108 and 53 mild to moderate bleeds in the rFVIIa and pd-aPCC groups, respectively. Although re-bleeding rates were similar in both groups, deeper analyses revealed significant differences in time to bleed resolution: 93.8% of bleeds treated with rFVIIa were resolved within less than 12h, versus 60.4% with pd-aPCC (P<0.001). Mean total cost/bleed was lower with rFVIIa (336,852 [median, 290,696] CZK; eur12,760 [11,011]) than pd-aPCC (522,768 [341,310] CZK; eur19,802 [12,928]) (P=0.002). Results were maintained after controlling for potential co-variables (bleed nature, time to treatment, target joints). Conclusions The lower total treatment costs per bleed with rFVIIa than pd-aPCC suggest that first-line rFVIIa is more cost-effective than pd-aPCC in mild to moderate bleeds. Time to bleed resolution was also significantly shorter with rFVIIa. These results were maintained when controlled for potential confounders.

Citovat

SALAJ, Peter; Miroslav PENKA; Petr SMEJKAL; Vera GEIEROVA; Petra OVESNÁ; Petr BRABEC; Petr CETKOVSKÝ; Radovan KUBES; Johan MESTERTON a Peter LINDGREN. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic. Thrombosis Research. 2012, roč. 129, č. 5, s. "e233"-"e237", 5 s. ISSN 0049-3848. Dostupné z: https://doi.org/10.1016/j.thromres.2012.02.005.

@article{992918,
   author = {Salaj, Peter and Penka, Miroslav and Smejkal, Petr and Geierova, Vera and Ovesná, Petra and Brabec, Petr and Cetkovský, Petr and Kubes, Radovan and Mesterton, Johan and Lindgren, Peter},
   article_number = {5},
   doi = {https://doi.org/10.1016/j.thromres.2012.02.005},
   keywords = {Cost-effectiveness; Haemophilia; Plasma-derived activated prothrombin complex concentrate; Recombinant factor VIIa; Registry},
   language = {eng},
   issn = {0049-3848},
   journal = {Thrombosis Research},
   title = {Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic},
   volume = {129},
   year = {2012}
}

TY  - JOUR
ID  - 992918
AU  - Salaj, Peter - Penka, Miroslav - Smejkal, Petr - Geierova, Vera - Ovesná, Petra - Brabec, Petr - Cetkovský, Petr - Kubes, Radovan - Mesterton, Johan - Lindgren, Peter
PY  - 2012
TI  - Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic
JF  - Thrombosis Research
VL  - 129
IS  - 5
SP  - "e233"-"e237"
EP  - "e233"-"e237"
SN  - 00493848
KW  - Cost-effectiveness
KW  - Haemophilia
KW  - Plasma-derived activated prothrombin complex concentrate
KW  - Recombinant factor VIIa
KW  - Registry
N2  - Several studies suggest that recombinant activated factor VII (rFVIIa) is more cost-effective than plasma-derived activated prothrombin complex concentrate (pd-aPCC) in haemophilia with inhibitors. However, most do not consider differences between treated patients. This study compared the pharmacoeconomics of rFVIIa versus pd-aPCC treatment of mild to moderate bleeds in inhibitor patients, taking co-variables into account. Methods The HemoRec and HemIS registries capture exhaustive bleeding data in inhibitor patients in the Czech Republic. For each bleed, patient and bleed characteristics, treatment outcomes and bypassing agent use were retrospectively analysed, and direct costs of care per bleed calculated. Generalised Linear Model regression methods with cluster effect were employed to account for the possibility of several bleedings from the same patient. Results There were 108 and 53 mild to moderate bleeds in the rFVIIa and pd-aPCC groups, respectively. Although re-bleeding rates were similar in both groups, deeper analyses revealed significant differences in time to bleed resolution: 93.8% of bleeds treated with rFVIIa were resolved within less than 12h, versus 60.4% with pd-aPCC (P<0.001). Mean total cost/bleed was lower with rFVIIa (336,852 [median, 290,696] CZK; eur12,760 [11,011]) than pd-aPCC (522,768 [341,310] CZK; eur19,802 [12,928]) (P=0.002). Results were maintained after controlling for potential co-variables (bleed nature, time to treatment, target joints). Conclusions The lower total treatment costs per bleed with rFVIIa than pd-aPCC suggest that first-line rFVIIa is more cost-effective than pd-aPCC in mild to moderate bleeds. Time to bleed resolution was also significantly shorter with rFVIIa. These results were maintained when controlled for potential confounders.
ER  -

SALAJ, Peter; Miroslav PENKA; Petr SMEJKAL; Vera GEIEROVA; Petra OVESNÁ; Petr BRABEC; Petr CETKOVSKÝ; Radovan KUBES; Johan MESTERTON a Peter LINDGREN. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic. \textit{Thrombosis Research}. 2012, roč.~129, č.~5, s.~''e233''-''e237'', 5 s. ISSN~0049-3848. Dostupné z: https://doi.org/10.1016/j.thromres.2012.02.005.

Přehled o publikaci